Arnulf Stenzl1, Curtis Dunshee2, Ugo De Giorgi3, Boris Alekseev4, Taro Iguchi5, Russell Z Szmulewitz6, Thomas W Flaig7, Bertrand Tombal8, Robert Morlock9, Cristina Ivanescu10, Krishnan Ramaswamy11, Fred Saad12, Andrew J Armstrong13. 1. Department of Urology, University Hospital, Eberhard Karls University of Tübingen, Tübingen, Germany. Electronic address: arnulf.stenzl@med.uni-tuebingen.de. 2. Urological Associates of Southern Arizona, Tucson, AZ, USA. 3. Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Meldola, Italy. 4. Herzen Moscow Cancer Research Institute, Moscow, Russia. 5. Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan. 6. Department of Medicine, The University of Chicago, Chicago, IL, USA. 7. Division of Medical Oncology, School of Medicine, University of Colorado, Aurora, CO, USA. 8. Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium. 9. Astellas Pharma Inc., Northbrook, IL, USA. 10. IQVIA, Amsterdam-Zuidoost, The Netherlands. 11. Global HEOR, Pfizer Inc., New York, NY, USA. 12. Centre Hospitalier de l'Université de Montréal, Montréal, Canada. 13. Duke Cancer Institute Center for Prostate and Urologic Cancer, Durham, NC, USA.
Abstract
BACKGROUND: In the ARCHES study in metastatic hormone-sensitive prostate cancer (mHSPC), enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) versus ADT alone. OBJECTIVE: To evaluate patient-reported outcomes (PROs) to week 73. DESIGN, SETTING, AND PARTICIPANTS: ARCHES (NCT02677896) was a randomised, double-blind, placebo-controlled, phase 3 study in mHSPC patients. INTERVENTION: Enzalutamide (160 mg/day) plus ADT or placebo plus ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PROs were assessed at baseline, week 13, and every 12 wk until disease progression using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate 25 (QLQ-PR25), Functional Assessment of Cancer Therapy-Prostate (FACT-P), Brief Pain Inventory Short Form, and EuroQoL 5-Dimensions, 5-Levels (EQ-5D-5 L) instruments. Endpoints included time to first (TTFD) and first confirmed (TTFCD) clinically meaningful deterioration (using predefined questionnaire thresholds) in health-related quality of life (HRQoL) and pain. RESULTS AND LIMITATIONS: A total of 1150 patients receivedADT plus enzalutamide (n = 574) or placebo (n = 576). Baseline PRO scores indicated high HRQoL and low pain, which was generally maintained in both groups. There were no statistically significant (nominal p > 0.05) between-group differences that occurred in both TTFD and TTFCD together for QLQ-PR25 and FACT-P scores. Enzalutamide significantly delayed TTFD in worst pain (by ∼3 mo; nominal p = 0.032), pain severity (nominal p = 0.021), and EQ-5D-5 L visual analogue scale score (nominal p = 0.0070) versus placebo (not significant for confirmed deterioration for pain outcomes). Enzalutamide delays deterioration in several HRQoL subscales and pain severity in high-volume disease. CONCLUSIONS:Enzalutamide plus ADT enables men with mHSPC to maintain high-functioning HRQoL and low symptom burden. PATIENT SUMMARY: This study examined the effect on health-related quality of life and pain of adding enzalutamide or placebo to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer. Addition of enzalutamide allowed patients to maintain their health-related quality of life.
RCT Entities:
BACKGROUND: In the ARCHES study in metastatic hormone-sensitive prostate cancer (mHSPC), enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) versus ADT alone. OBJECTIVE: To evaluate patient-reported outcomes (PROs) to week 73. DESIGN, SETTING, AND PARTICIPANTS: ARCHES (NCT02677896) was a randomised, double-blind, placebo-controlled, phase 3 study in mHSPC patients. INTERVENTION: Enzalutamide (160 mg/day) plus ADT or placebo plus ADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PROs were assessed at baseline, week 13, and every 12 wk until disease progression using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Prostate 25 (QLQ-PR25), Functional Assessment of Cancer Therapy-Prostate (FACT-P), Brief Pain Inventory Short Form, and EuroQoL 5-Dimensions, 5-Levels (EQ-5D-5 L) instruments. Endpoints included time to first (TTFD) and first confirmed (TTFCD) clinically meaningful deterioration (using predefined questionnaire thresholds) in health-related quality of life (HRQoL) and pain. RESULTS AND LIMITATIONS: A total of 1150 patients received ADT plus enzalutamide (n = 574) or placebo (n = 576). Baseline PRO scores indicated high HRQoL and low pain, which was generally maintained in both groups. There were no statistically significant (nominal p > 0.05) between-group differences that occurred in both TTFD and TTFCD together for QLQ-PR25 and FACT-P scores. Enzalutamide significantly delayed TTFD in worst pain (by ∼3 mo; nominal p = 0.032), pain severity (nominal p = 0.021), and EQ-5D-5 L visual analogue scale score (nominal p = 0.0070) versus placebo (not significant for confirmed deterioration for pain outcomes). Enzalutamide delays deterioration in several HRQoL subscales and pain severity in high-volume disease. CONCLUSIONS:Enzalutamide plus ADT enables men with mHSPC to maintain high-functioning HRQoL and low symptom burden. PATIENT SUMMARY: This study examined the effect on health-related quality of life and pain of adding enzalutamide or placebo to androgen deprivation therapy for patients with metastatic hormone-sensitive prostate cancer. Addition of enzalutamide allowed patients to maintain their health-related quality of life.
Authors: Martin R Stockler; Andrew J Martin; Ian D Davis; Haryana M Dhillon; Stephen D Begbie; Kim N Chi; Simon Chowdhury; Xanthi Coskinas; Mark Frydenberg; Wendy E Hague; Lisa G Horvath; Anthony M Joshua; Nicola J Lawrence; Gavin M Marx; John McCaffrey; Ray McDermott; Margaret McJannett; Scott A North; Francis Parnis; Wendy R Parulekar; David W Pook; M Neil Reaume; Shahneen Sandhu; Alvin Tan; Thean Hsiang Tan; Alastair Thomson; Francisco Vera-Badillo; Scott G Williams; Diana G Winter; Sonia Yip; Alison Y Zhang; Robert R Zielinski; Christopher J Sweeney Journal: J Clin Oncol Date: 2021-12-20 Impact factor: 50.717
Authors: Heather Payne; Angus Robinson; Bernard Rappe; Serena Hilman; Ugo De Giorgi; Steven Joniau; Roberto Bordonaro; Stéphane Mallick; Louis-Marie Dourthe; Moisés Mira Flores; Josep Gumà; Benoit Baron; Aurea Duran; Alessandra Pranzo; Alexis Serikoff; David Mott; Mike Herdman; Marco Pavesi; Maria De Santis Journal: Int J Cancer Date: 2021-11-08 Impact factor: 7.316
Authors: Alexander Kretschmer; Roderick C N van den Bergh; Alberto Martini; Giancarlo Marra; Massimo Valerio; Igor Tsaur; Isabel Heidegger; Veeru Kasivisvanathan; Claudia Kesch; Felix Preisser; Christian D Fankhauser; Fabio Zattoni; Francesco Ceci; Jonathan Olivier; Peter Chiu; Ignacio Puche-Sanz; Constance Thibault; Giorgio Gandaglia; Derya Tilki Journal: Cancers (Basel) Date: 2021-12-29 Impact factor: 6.639
Authors: Evie E M Kolsteren; Esther Deuning-Smit; Alanna K Chu; Yvonne C W van der Hoeven; Judith B Prins; Winette T A van der Graaf; Carla M L van Herpen; Inge M van Oort; Sophie Lebel; Belinda Thewes; Linda Kwakkenbos; José A E Custers Journal: Cancers (Basel) Date: 2022-08-11 Impact factor: 6.575
Authors: Keiichiro Mori; Hadi Mostafaei; Reza Sari Motlagh; Benjamin Pradere; Fahad Quhal; Ekaterina Laukhtina; Victor M Schuettfort; Gero Kramer; Mohammad Abufaraj; Pierre I Karakiewicz; Takahiro Kimura; Shin Egawa; Shahrokh F Shariat Journal: BJU Int Date: 2021-07-21 Impact factor: 5.969